Product Description
Mechanisms of Action: GPIIb/IIIa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Other|Raynaud Disease|Scleroderma, Systemic|Scleroderma, Diffuse|Scleroderma, General
Phase 1: Acute Coronary Syndrome|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| APD791-204 | P2 |
Terminated |
Scleroderma, General|Scleroderma, Systemic|Raynaud Disease|Scleroderma, Diffuse |
2022-09-02 |
|
| APD791-202 | P2 |
Terminated |
Other |
2022-08-23 |
|
| 2020-000238-16 | P2 |
Terminated |
Unknown |
2022-08-23 |
|
| ID-TMG-102 | P1 |
Terminated |
Acute Coronary Syndrome |
2016-04-01 |
22% |